Literature DB >> 2906246

Electrophysiologic effects of saterinone and milrinone in the isolated guinea pig myocardium.

H Iven1, H Brasch, B I Armah.   

Abstract

The positive inotropic agent milrinone and the newly synthesized compound saterinone [+/-)-1,2-dihydro-5-[4-[2-hydroxy-3-[4-(2-methoxyphenyl)-1-piperazinyl] propoxy]phenyl]-6-methyl-2-oxo-3-pyridine-carbonitrile, BDF 8634) dose-dependently increased the contractile force of guinea pig left atria. During a 90-min exposure, 10(-4) mol/l saterinone caused a continuous increase of the functional refractory period (FRP), while the initial positive inotropic effect faded gradually. No change of the FRP was observed with milrinone. Saterinone (10(-4) mol/l) also increased the action potential duration and the FRP of guinea pig papillary muscles, while milrinone had no influence on either parameter. Both milrinone and saterinone increased the amplitude, depolarization velocity and duration of slow response action potentials in K+-depolarized muscles. These effects appeared in the presence of tetrodotoxin or propranolol and could be reversed by carbachol. It is concluded that saterinone increases the force of contraction and the slow inward current by inhibiting cardiac phosphodiesterase. The increase of the FRP may be attributed to a decrease of the membrane K+ conductance.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2906246

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  2 in total

1.  Actions of the phosphodiesterase inhibitor zardaverine on guinea-pig ventricular muscle.

Authors:  M Galvan; C Schudt
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-08       Impact factor: 3.000

2.  Infrared assisted production of 3,4-dihydro-2(1H)-pyridones in solvent-free conditions.

Authors:  M Olivia Noguez; Vanessa Marcelino; Hortensia Rodríguez; Osnieski Martín; Joel O Martínez; Gabriel A Arroyo; Francisco J Pérez; Margarita Suárez; René Miranda
Journal:  Int J Mol Sci       Date:  2011-04-18       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.